Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056. - Test2 - elhamkhani - TriplyDB

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

http://www.wikidata.org/entity/Q34157712

about

On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome Conceptualizing neurodevelopmental disorders through a mechanistic understanding of fragile X syndrome and Williams syndrome Fragile x syndrome Transcriptional Reactivation of the FMR1 Gene. A Possible Approach to the Treatment of the Fragile X Syndrome Synaptic Plasticity, a Prominent Contributor to the Anxiety in Fragile X Syndrome Emerging pharmacologic treatment options for fragile X syndrome Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments Fragile X syndrome and targeted treatment trials.The role of glutamate and its receptors in autism and the use of glutamate receptor antagonists in treatment.Treatment of neurodevelopmental disorders in adulthood Targeted pharmacological treatment of autism spectrum disorders: fragile X and Rett syndromes Developing Medications Targeting Glutamatergic Dysfunction in Autism: Progress to Date The unstable repeats--three evolving faces of neurological disease Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism.Therapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back Advancing the understanding of autism disease mechanisms through genetics Review of targeted treatments in fragile X syndrome Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis The NIH Toolbox Cognitive Battery for intellectual disabilities: three preliminary studies and future directions De Novo Gene Disruptions in Children on the Autistic Spectrum Enhanced expression of ADCY1 underlies aberrant neuronal signalling and behaviour in a syndromic autism model.Electrocortical changes associated with minocycline treatment in fragile X syndrome.Progress toward therapeutic potential for AFQ056 in Fragile X syndrome.Psychophysiological responses to emotional stimuli in children and adolescents with autism and fragile X syndrome.From FMRP function to potential therapies for fragile X syndrome.Influence of stimulant-induced hyperactivity on social approach in the BTBR mouse model of autism Allosteric modulation of metabotropic glutamate receptors.mGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotion CGG repeat in the FMR1 gene: size matters Disrupted Homer scaffolds mediate abnormal mGluR5 function in a mouse model of fragile X syndrome.Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome.Topological methods reveal high and low functioning neuro-phenotypes within fragile X syndrome.Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.Psychiatric symptoms in boys with fragile X syndrome: a comparison with nonsyndromic autism spectrum disorder.Advanced pharmacotherapy evidenced by pathogenesis of autism spectrum disorder.Epilepsy drives autism in neurodevelopmental disorders.Fragile X Syndrome: Prevalence, Treatment, and Prevention in China Lithium: a promising treatment for fragile X syndrome.FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States

P2860

Q22241936-242D7558-92E1-4617-8718-4106F92C67E8 Q24613296-086D2483-5813-4128-8948-CC9851FE94A5 Q24633000-E17E2465-B4BA-45D9-ACE4-13C31E8AD29F Q26739927-E061FF5C-B318-426B-B193-2521479CA46E Q26745117-5D443DFC-DDCD-4F88-84F2-E0A1D5028106 Q26829152-2491A770-3F9C-463F-857F-E035AC639024 Q26850307-151E1170-17FC-4A56-8BD2-70AA528FC535 Q26865162-685E0D49-B845-441D-A0E0-DE5E63992DA6 Q26998975-7762A644-4142-4372-A7E1-F96AF906E466 Q27000307-5A45C5F9-AF5E-44D6-BEDB-2B2DDAE819F5 Q27023257-7AF75599-F662-434A-A107-4E93DB7A6463 Q27025683-C77B2E42-D052-4D3F-A82F-44B5361288EC Q27025923-8BF6E6B6-6BCB-4D55-B669-F1193DB33CF6 Q27329063-C0374047-C2A0-4A23-AA2C-C31E0D23B0C8 Q27337360-2FA3D03F-8A1F-4305-9741-114DD5EC0AA0 Q28069757-817F0552-5265-45D5-95A3-4EF22A323405 Q28077180-A1F3E418-548A-4DC0-BB03-578F96A45244 Q28390236-FEC24DF8-2603-4F95-8DB7-499362E13AA0 Q29109561-3A1C5E34-1687-4A29-9A82-F9085D16A78E Q29394534-DDF91D0A-17CD-4C14-A9CB-93510ABF18B6 Q30362378-234FDDA0-5DFE-41B7-B69B-998B42FF3001 Q30378165-1ADD6EA7-B51E-4AA4-8DEE-98E4B430FF12 Q30383696-B4B1A91B-6744-4E06-8C05-B5F54E9A2701 Q30394865-4C73CC93-B6B4-450C-803E-1CC36A8E31F9 Q30410502-C628877A-44FC-4083-AF64-C805D26451CE Q30439243-BCD23EB4-EC87-4FF5-8178-463BEDBB57DA Q30448534-6FC03E2C-6AB3-45E3-B602-263CC77FBA70 Q30450936-7730BAFB-6A3A-474E-8BC8-8DB4686CE912 Q30464036-65C5A962-7F82-48ED-914E-CCC884B5CC62 Q30505749-7B7399C4-5B61-4B46-969C-8E1A82719CE4 Q30574939-4BA3F019-3B86-4B61-9175-8B614616C33A Q30585077-B46C6DE6-69AB-421B-A4E0-8759E56D7731 Q30709836-1E034310-2A31-492F-BA98-FFC6B4E9DD26 Q31043571-72481053-8885-4F72-9EB8-A91FC28A7D54 Q33565886-A8617386-D1BD-4A55-81B3-06A353C2A62C Q33618938-225C7036-8685-4232-87BF-6EBE03A85DFA Q33733577-510AD54F-B66F-49BE-93A0-0C46098714D6 Q33766106-6C3AB5F6-F4EE-4760-AB5B-9D2ECAA9B63D Q33777951-FD20E2A9-7139-4293-ADE8-3DBE78559721 Q33781086-80658B6D-6860-4FD7-98DF-2FDC272E75C3

P2860

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

http://www.wikidata.org/entity/Q34157712

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@ast

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@en

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@nl

type

label

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@ast

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@en

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@nl

prefLabel

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@ast

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@en

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@nl

P1433

Q34157712-B4B6E112-EA05-4F99-BF1C-705D1E849E0D

P1476

Q34157712-67892930-C1B5-412D-8DA1-3CC925917414

P2093

Q34157712-0562FD95-36F6-4F6B-9E2A-18CAC8EC4BF9

Q34157712-080EF241-9843-4C12-946E-0D69AAAA3B32

Q34157712-0DCF495E-FB67-4497-BB89-1685A2E5CA21

Q34157712-105D1B96-FA63-474D-8E08-D9B9D9AFFB04

Q34157712-19CB719E-88E0-4EE7-9282-78E5CFA3874C

Q34157712-1EB35C11-8300-491A-A743-0538C0A4FF7B

Q34157712-35B8D775-3900-451A-BF89-2F1E6E15621B

Q34157712-428BF382-7020-4622-89C8-3C8A58EA5190

Q34157712-580C4075-A30C-40BE-B041-9A39B8204041

Q34157712-6363D631-0E5D-4646-8ABC-406FEF95218A

P2860

Q34157712-0C25A5E7-39BA-41C7-B5E1-07103A064A20

Q34157712-0D560EB0-6B1E-40AC-977F-1A9DC36DC530

Q34157712-1028E7AC-E6DD-4ECC-8EC4-AFEB6571CB44

Q34157712-4656A6D8-E283-4385-8E5A-FAEB096836E1

Q34157712-47C61007-996F-4A4E-B430-7008834D6FF7

Q34157712-52CD78E7-AEB8-4902-A1B1-1CD4FD8A5A2A

Q34157712-A38ED0ED-BFAA-48A7-91CE-42757D890CC0

Q34157712-AA4B65DA-2CE6-454A-A3FA-A6FEBFBEEAEE

Q34157712-CE8E67B2-F11F-4376-9270-8B13233A3479

Q34157712-D4B93574-3A99-431E-B1C2-1E864308DEBC

P304

Q34157712-F2100A31-5582-4899-9D5E-F8B797E991B9

P31

Q34157712-5A999E91-80BC-4534-A1BE-6564E0615587

P356

Q34157712-BAD15C13-866C-45FE-B132-15A909059B1E

P407

Q34157712-4BE67070-D478-4139-9E55-1F777FB70F03

P433

Q34157712-9D38798A-56E6-470B-92E2-F26C48D60381

P478

Q34157712-E5B2A5BE-A163-409D-8DA4-C416A422EB7E

P50

Q34157712-154DF432-A034-4744-869E-5BF10E103213

Q34157712-23201CF5-1B19-467E-9625-606D0CA27560

Q34157712-3B9F7CC8-41CB-4FF4-83A1-F7FF0EEBADB9

Q34157712-78959F43-3007-40E1-A2A2-8775E985C88B

Q34157712-7B9D7C17-C5EA-49E2-AB85-EC50C331C226

P577

Q34157712-36AAF154-24E8-43EC-A5A4-1540CBADF7FD

P698

Q34157712-A1B71B41-63A2-4305-889E-2958D375B971

P356

SCITRANSLMED.3001708

P1433

Science Translational Medicine

P1476

Epigenetic modification of the ...... the mGluR5 antagonist AFQ056.

@en

P2093

Amandine Brun

http://www.w3.org/2001/XMLSchema#string

Annette Floesser

http://www.w3.org/2001/XMLSchema#string

Aurore Curie

http://www.w3.org/2001/XMLSchema#string

Baltazar Gomez-Mancilla

http://www.w3.org/2001/XMLSchema#string

Charles Paulding

http://www.w3.org/2001/XMLSchema#string

Danielle Martinet

http://www.w3.org/2001/XMLSchema#string

Donald Johns

http://www.w3.org/2001/XMLSchema#string

Elizabeth Berry-Kravis

http://www.w3.org/2001/XMLSchema#string

Fabrizio Gasparini

http://www.w3.org/2001/XMLSchema#string

Gerald Bussy

http://www.w3.org/2001/XMLSchema#string

P2860

Advances in the treatment of fragile X syndrome

A pilot open label, single dose trial of fenobam in adults with fragile X syndrome.

The fragile X syndrome protein FMRP associates with BC1 RNA and regulates the translation of specific mRNAs at synapses

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

The mGluR theory of fragile X mental retardation

Varieties of repetitive behavior in autism: comparisons to mental retardation.

Placebo effects in developmental disabilities: implications for research and practice.

Fragile X mental retardation protein replacement restores hippocampal synaptic function in a mouse model of fragile X syndrome.

Contribution of mGluR and Fmr1 functional pathways to neurite morphogenesis, craniofacial development and fragile X syndrome.

Transcription of the FMR1 gene in individuals with fragile X syndrome.

P304

64ra1

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.3001708

http://www.w3.org/2001/XMLSchema#string

P407

P433

64

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Nouchine Hadjikhani

Jacques S. Beckmann

Feliciano J Ramos

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21209411

http://www.w3.org/2001/XMLSchema#string